Global Opioids Agonist Drugs Market

Opioids Agonist Drugs Comprehensive Study by Type (Morphine, Codeine, Fentanyl, Meperidine), Application (Pain Management, Cough Supression, Diarrhea Suppresion), Receptor Binding (Strong Agonist, Mild to Moderate Agonist) Players and Region - Global Market Outlook to 2026

Opioids Agonist Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Opioids Agonist Drugs Market Scope
Over the past few years, there has been a significant rise in a number of people additives towards opioid agonist drugs overdoses in the United States every day with figure stood up to 115 death toll. It has also witnessed that 21 to 29 percent of patients who are prescribed opioids for chronic pain misuse them, with 8 to 12 percent developing an opioid use disorder. The major companies are organized awareness programs in Asia-Pacific and Middle East region to prescribe painkillers to help patients overcome opiophobia. The opioids drugs is a type of narcotic pain medication that applicable for treatment of severe pain. It is used as an anesthesia, cough suppressant, diarrhea suppressant and to reduce surgical pain. As the numbers of critically ill patients are increasing, demand for orthopedic diseases is also on the rise, leading to a growing demand for opioids drugs.

Research Analyst at AMA estimates that European and United States Players will contribute to the maximum growth of Global Opioids Agonist Drugs market throughout the predicted period.

Purdue Pharma L.P (United States), Allergan PLC (Ireland), Sanofi S.A (France), Pfizer, Inc. (United States), Janssen Pharmaceuticals, Inc. (Belgium), Endo Pharmaceuticals, Inc (United States), Actavis Plc (United States), Egalet Corporation (United States), Sun Pharmaceuticals (India), Boehringer Ingelheim GmbH (Germany). and Titan Pharmaceuticals, Inc. (TTNP) (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Mallinckrodt Pharmaceuticals (United Kingdom) and Allergan, Plc (Ireland).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
The study have segmented the market of Global Opioids Agonist Drugs market by Type (Morphine, Codeine, Fentanyl and Meperidine), by Application (Pain Management, Cough Supression and Diarrhea Suppresion) and Region with country level break-up.

On the basis of geography, the market of Opioids Agonist Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In April 2019, U.S. Food and Drug Administration launched a public education campaign which is beneficial in providing safe removal of unused opioid pain medicines from homes. It also introduced a “Remove and Risk” Campaign that telecast in television, radio and print public announcements that can be used by different organizations, individuals and healthcare providers.
In January 2019, Medicare has introduced new opioid prescribing guidelines which will affect Medicare Part D beneficiaries. Part D plans are projected to limit early opioid dispensing to a 7-day supply or less. This guideline will impact Medicare patients who have not filled an opioid prescription lately. The suppliers then have to predefine the supply timeline or the consumers have to predetermine the lead. Thus, the new guidelines are expected to limit the abuse rate in the United States.
“According to Department of Health and Human Services, Its launched some strategy to combat against opioids addiction, the strategy consist of prevention, treatment and recovery services, data on the epidemic, pain management, targeting of overdose-reversing drugs and research on pain and addiction.”

Market Trend
  • Increasing Use of Methadone, Buprenorphine, and Extended-Release Naltrexone
  • Growing Adoption of Opioids Drugs in Surgical Treatments and Pain Management

Market Drivers
  • Upsurging Geriatric Population leading to Increased Prevalence of Cancer, Postsurgical Pain, Lower Back Pain, and Many Others
  • Increasing Surgical Procedures and Technological Advancements

Opportunities
  • Rising Demands of Opioids Drugs in Cough Suppressant and Diarrhea Suppressant.
  • Growing Palliative Care Facilities Boost the Opioids Drugs Market

Restraints
  • Stringent Government Regulations on Manufacturing Opioids Agonist Drugs
  • Continues Products Development and R&D has Introduced Number of Cheaper Substitutes

Challenges
  • Legalization of Cannabis as Alternatives of Cannabis may challenge the Market of Opioids Drugs


Key Target Audience
Opioids Agonist Drugs Manufacturers, Opioids Agonist Drugs Distributors and Suppliers, Opioids Agonist Drugs International Traders, Pharmaceutical Industry Associations, Research and Development Institutes, Government Agencies and Others

Report Objectives / Segmentation Covered

By Type
  • Morphine
  • Codeine
  • Fentanyl
  • Meperidine
By Application
  • Pain Management
  • Cough Supression
  • Diarrhea Suppresion
By Receptor Binding
  • Strong Agonist
  • Mild to Moderate Agonist

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Upsurging Geriatric Population leading to Increased Prevalence of Cancer, Postsurgical Pain, Lower Back Pain, and Many Others
      • 3.2.2. Increasing Surgical Procedures and Technological Advancements
    • 3.3. Market Challenges
      • 3.3.1. Legalization of Cannabis as Alternatives of Cannabis may challenge the Market of Opioids Drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Use of Methadone, Buprenorphine, and Extended-Release Naltrexone
      • 3.4.2. Growing Adoption of Opioids Drugs in Surgical Treatments and Pain Management
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Opioids Agonist Drugs, by Type, Application, Receptor Binding and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Opioids Agonist Drugs (Value)
      • 5.2.1. Global Opioids Agonist Drugs by: Type (Value)
        • 5.2.1.1. Morphine
        • 5.2.1.2. Codeine
        • 5.2.1.3. Fentanyl
        • 5.2.1.4. Meperidine
      • 5.2.2. Global Opioids Agonist Drugs by: Application (Value)
        • 5.2.2.1. Pain Management
        • 5.2.2.2. Cough Supression
        • 5.2.2.3. Diarrhea Suppresion
      • 5.2.3. Global Opioids Agonist Drugs by: Receptor Binding (Value)
        • 5.2.3.1. Strong Agonist
        • 5.2.3.2. Mild to Moderate Agonist
      • 5.2.4. Global Opioids Agonist Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Opioids Agonist Drugs (Volume)
      • 5.3.1. Global Opioids Agonist Drugs by: Type (Volume)
        • 5.3.1.1. Morphine
        • 5.3.1.2. Codeine
        • 5.3.1.3. Fentanyl
        • 5.3.1.4. Meperidine
      • 5.3.2. Global Opioids Agonist Drugs by: Application (Volume)
        • 5.3.2.1. Pain Management
        • 5.3.2.2. Cough Supression
        • 5.3.2.3. Diarrhea Suppresion
      • 5.3.3. Global Opioids Agonist Drugs by: Receptor Binding (Volume)
        • 5.3.3.1. Strong Agonist
        • 5.3.3.2. Mild to Moderate Agonist
      • 5.3.4. Global Opioids Agonist Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Opioids Agonist Drugs (Price)
      • 5.4.1. Global Opioids Agonist Drugs by: Type (Price)
  • 6. Opioids Agonist Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Purdue Pharma L.P (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan PLC (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Janssen Pharmaceuticals, Inc. (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Endo Pharmaceuticals, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Actavis Plc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Egalet Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sun Pharmaceuticals (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Boehringer Ingelheim GmbH (Germany).
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Titan Pharmaceuticals, Inc. (TTNP) (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Opioids Agonist Drugs Sale, by Type, Application, Receptor Binding and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Opioids Agonist Drugs (Value)
      • 7.2.1. Global Opioids Agonist Drugs by: Type (Value)
        • 7.2.1.1. Morphine
        • 7.2.1.2. Codeine
        • 7.2.1.3. Fentanyl
        • 7.2.1.4. Meperidine
      • 7.2.2. Global Opioids Agonist Drugs by: Application (Value)
        • 7.2.2.1. Pain Management
        • 7.2.2.2. Cough Supression
        • 7.2.2.3. Diarrhea Suppresion
      • 7.2.3. Global Opioids Agonist Drugs by: Receptor Binding (Value)
        • 7.2.3.1. Strong Agonist
        • 7.2.3.2. Mild to Moderate Agonist
      • 7.2.4. Global Opioids Agonist Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Opioids Agonist Drugs (Volume)
      • 7.3.1. Global Opioids Agonist Drugs by: Type (Volume)
        • 7.3.1.1. Morphine
        • 7.3.1.2. Codeine
        • 7.3.1.3. Fentanyl
        • 7.3.1.4. Meperidine
      • 7.3.2. Global Opioids Agonist Drugs by: Application (Volume)
        • 7.3.2.1. Pain Management
        • 7.3.2.2. Cough Supression
        • 7.3.2.3. Diarrhea Suppresion
      • 7.3.3. Global Opioids Agonist Drugs by: Receptor Binding (Volume)
        • 7.3.3.1. Strong Agonist
        • 7.3.3.2. Mild to Moderate Agonist
      • 7.3.4. Global Opioids Agonist Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Opioids Agonist Drugs (Price)
      • 7.4.1. Global Opioids Agonist Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Opioids Agonist Drugs: by Type(USD Million)
  • Table 2. Opioids Agonist Drugs Morphine , by Region USD Million (2015-2020)
  • Table 3. Opioids Agonist Drugs Codeine , by Region USD Million (2015-2020)
  • Table 4. Opioids Agonist Drugs Fentanyl , by Region USD Million (2015-2020)
  • Table 5. Opioids Agonist Drugs Meperidine , by Region USD Million (2015-2020)
  • Table 6. Opioids Agonist Drugs: by Application(USD Million)
  • Table 7. Opioids Agonist Drugs Pain Management , by Region USD Million (2015-2020)
  • Table 8. Opioids Agonist Drugs Cough Supression , by Region USD Million (2015-2020)
  • Table 9. Opioids Agonist Drugs Diarrhea Suppresion , by Region USD Million (2015-2020)
  • Table 10. Opioids Agonist Drugs: by Receptor Binding(USD Million)
  • Table 11. Opioids Agonist Drugs Strong Agonist , by Region USD Million (2015-2020)
  • Table 12. Opioids Agonist Drugs Mild to Moderate Agonist , by Region USD Million (2015-2020)
  • Table 13. South America Opioids Agonist Drugs, by Country USD Million (2015-2020)
  • Table 14. South America Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 15. South America Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 16. South America Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 17. Brazil Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 18. Brazil Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 19. Brazil Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 20. Argentina Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 21. Argentina Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 22. Argentina Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 23. Rest of South America Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 24. Rest of South America Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 26. Asia Pacific Opioids Agonist Drugs, by Country USD Million (2015-2020)
  • Table 27. Asia Pacific Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 28. Asia Pacific Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 30. China Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 31. China Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 32. China Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 33. Japan Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 34. Japan Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 35. Japan Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 36. India Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 37. India Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 38. India Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 39. South Korea Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 40. South Korea Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 41. South Korea Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 42. Taiwan Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 43. Taiwan Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 44. Taiwan Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 45. Australia Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 46. Australia Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 47. Australia Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 51. Europe Opioids Agonist Drugs, by Country USD Million (2015-2020)
  • Table 52. Europe Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 53. Europe Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 54. Europe Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 55. Germany Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 56. Germany Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 57. Germany Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 58. France Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 59. France Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 60. France Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 61. Italy Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 62. Italy Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 63. Italy Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 64. United Kingdom Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 65. United Kingdom Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 67. Netherlands Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 68. Netherlands Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 69. Netherlands Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 70. Rest of Europe Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 71. Rest of Europe Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 73. MEA Opioids Agonist Drugs, by Country USD Million (2015-2020)
  • Table 74. MEA Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 75. MEA Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 76. MEA Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 77. Middle East Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 78. Middle East Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 79. Middle East Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 80. Africa Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 81. Africa Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 82. Africa Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 83. North America Opioids Agonist Drugs, by Country USD Million (2015-2020)
  • Table 84. North America Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 85. North America Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 86. North America Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 87. United States Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 88. United States Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 89. United States Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 90. Canada Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 91. Canada Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 92. Canada Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 93. Mexico Opioids Agonist Drugs, by Type USD Million (2015-2020)
  • Table 94. Mexico Opioids Agonist Drugs, by Application USD Million (2015-2020)
  • Table 95. Mexico Opioids Agonist Drugs, by Receptor Binding USD Million (2015-2020)
  • Table 96. Opioids Agonist Drugs Sales: by Type(K Units)
  • Table 97. Opioids Agonist Drugs Sales Morphine , by Region K Units (2015-2020)
  • Table 98. Opioids Agonist Drugs Sales Codeine , by Region K Units (2015-2020)
  • Table 99. Opioids Agonist Drugs Sales Fentanyl , by Region K Units (2015-2020)
  • Table 100. Opioids Agonist Drugs Sales Meperidine , by Region K Units (2015-2020)
  • Table 101. Opioids Agonist Drugs Sales: by Application(K Units)
  • Table 102. Opioids Agonist Drugs Sales Pain Management , by Region K Units (2015-2020)
  • Table 103. Opioids Agonist Drugs Sales Cough Supression , by Region K Units (2015-2020)
  • Table 104. Opioids Agonist Drugs Sales Diarrhea Suppresion , by Region K Units (2015-2020)
  • Table 105. Opioids Agonist Drugs Sales: by Receptor Binding(K Units)
  • Table 106. Opioids Agonist Drugs Sales Strong Agonist , by Region K Units (2015-2020)
  • Table 107. Opioids Agonist Drugs Sales Mild to Moderate Agonist , by Region K Units (2015-2020)
  • Table 108. South America Opioids Agonist Drugs Sales, by Country K Units (2015-2020)
  • Table 109. South America Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 110. South America Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 111. South America Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 112. Brazil Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 113. Brazil Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 114. Brazil Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 115. Argentina Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 116. Argentina Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 117. Argentina Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 118. Rest of South America Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 119. Rest of South America Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 120. Rest of South America Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 121. Asia Pacific Opioids Agonist Drugs Sales, by Country K Units (2015-2020)
  • Table 122. Asia Pacific Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 123. Asia Pacific Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 124. Asia Pacific Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 125. China Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 126. China Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 127. China Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 128. Japan Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 129. Japan Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 130. Japan Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 131. India Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 132. India Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 133. India Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 134. South Korea Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 135. South Korea Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 136. South Korea Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 137. Taiwan Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 138. Taiwan Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 139. Taiwan Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 140. Australia Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 141. Australia Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 142. Australia Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 143. Rest of Asia-Pacific Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 144. Rest of Asia-Pacific Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 145. Rest of Asia-Pacific Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 146. Europe Opioids Agonist Drugs Sales, by Country K Units (2015-2020)
  • Table 147. Europe Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 148. Europe Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 149. Europe Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 150. Germany Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 151. Germany Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 152. Germany Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 153. France Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 154. France Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 155. France Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 156. Italy Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 157. Italy Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 158. Italy Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 159. United Kingdom Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 160. United Kingdom Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 161. United Kingdom Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 162. Netherlands Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 163. Netherlands Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 164. Netherlands Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 165. Rest of Europe Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 166. Rest of Europe Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 167. Rest of Europe Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 168. MEA Opioids Agonist Drugs Sales, by Country K Units (2015-2020)
  • Table 169. MEA Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 170. MEA Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 171. MEA Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 172. Middle East Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 173. Middle East Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 174. Middle East Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 175. Africa Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 176. Africa Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 177. Africa Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 178. North America Opioids Agonist Drugs Sales, by Country K Units (2015-2020)
  • Table 179. North America Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 180. North America Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 181. North America Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 182. United States Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 183. United States Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 184. United States Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 185. Canada Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 186. Canada Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 187. Canada Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 188. Mexico Opioids Agonist Drugs Sales, by Type K Units (2015-2020)
  • Table 189. Mexico Opioids Agonist Drugs Sales, by Application K Units (2015-2020)
  • Table 190. Mexico Opioids Agonist Drugs Sales, by Receptor Binding K Units (2015-2020)
  • Table 191. Opioids Agonist Drugs: by Type(USD/Units)
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Opioids Agonist Drugs: by Type(USD Million)
  • Table 204. Opioids Agonist Drugs Morphine , by Region USD Million (2021-2026)
  • Table 205. Opioids Agonist Drugs Codeine , by Region USD Million (2021-2026)
  • Table 206. Opioids Agonist Drugs Fentanyl , by Region USD Million (2021-2026)
  • Table 207. Opioids Agonist Drugs Meperidine , by Region USD Million (2021-2026)
  • Table 208. Opioids Agonist Drugs: by Application(USD Million)
  • Table 209. Opioids Agonist Drugs Pain Management , by Region USD Million (2021-2026)
  • Table 210. Opioids Agonist Drugs Cough Supression , by Region USD Million (2021-2026)
  • Table 211. Opioids Agonist Drugs Diarrhea Suppresion , by Region USD Million (2021-2026)
  • Table 212. Opioids Agonist Drugs: by Receptor Binding(USD Million)
  • Table 213. Opioids Agonist Drugs Strong Agonist , by Region USD Million (2021-2026)
  • Table 214. Opioids Agonist Drugs Mild to Moderate Agonist , by Region USD Million (2021-2026)
  • Table 215. South America Opioids Agonist Drugs, by Country USD Million (2021-2026)
  • Table 216. South America Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 217. South America Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 218. South America Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 219. Brazil Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 220. Brazil Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 221. Brazil Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 222. Argentina Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 223. Argentina Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 224. Argentina Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 225. Rest of South America Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 226. Rest of South America Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 227. Rest of South America Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 228. Asia Pacific Opioids Agonist Drugs, by Country USD Million (2021-2026)
  • Table 229. Asia Pacific Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 230. Asia Pacific Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 231. Asia Pacific Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 232. China Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 233. China Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 234. China Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 235. Japan Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 236. Japan Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 237. Japan Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 238. India Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 239. India Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 240. India Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 241. South Korea Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 242. South Korea Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 243. South Korea Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 244. Taiwan Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 245. Taiwan Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 246. Taiwan Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 247. Australia Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 248. Australia Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 249. Australia Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 250. Rest of Asia-Pacific Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 251. Rest of Asia-Pacific Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 252. Rest of Asia-Pacific Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 253. Europe Opioids Agonist Drugs, by Country USD Million (2021-2026)
  • Table 254. Europe Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 255. Europe Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 256. Europe Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 257. Germany Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 258. Germany Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 259. Germany Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 260. France Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 261. France Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 262. France Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 263. Italy Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 264. Italy Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 265. Italy Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 266. United Kingdom Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 267. United Kingdom Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 268. United Kingdom Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 269. Netherlands Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 270. Netherlands Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 271. Netherlands Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 272. Rest of Europe Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 273. Rest of Europe Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 274. Rest of Europe Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 275. MEA Opioids Agonist Drugs, by Country USD Million (2021-2026)
  • Table 276. MEA Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 277. MEA Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 278. MEA Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 279. Middle East Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 280. Middle East Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 281. Middle East Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 282. Africa Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 283. Africa Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 284. Africa Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 285. North America Opioids Agonist Drugs, by Country USD Million (2021-2026)
  • Table 286. North America Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 287. North America Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 288. North America Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 289. United States Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 290. United States Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 291. United States Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 292. Canada Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 293. Canada Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 294. Canada Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 295. Mexico Opioids Agonist Drugs, by Type USD Million (2021-2026)
  • Table 296. Mexico Opioids Agonist Drugs, by Application USD Million (2021-2026)
  • Table 297. Mexico Opioids Agonist Drugs, by Receptor Binding USD Million (2021-2026)
  • Table 298. Opioids Agonist Drugs Sales: by Type(K Units)
  • Table 299. Opioids Agonist Drugs Sales Morphine , by Region K Units (2021-2026)
  • Table 300. Opioids Agonist Drugs Sales Codeine , by Region K Units (2021-2026)
  • Table 301. Opioids Agonist Drugs Sales Fentanyl , by Region K Units (2021-2026)
  • Table 302. Opioids Agonist Drugs Sales Meperidine , by Region K Units (2021-2026)
  • Table 303. Opioids Agonist Drugs Sales: by Application(K Units)
  • Table 304. Opioids Agonist Drugs Sales Pain Management , by Region K Units (2021-2026)
  • Table 305. Opioids Agonist Drugs Sales Cough Supression , by Region K Units (2021-2026)
  • Table 306. Opioids Agonist Drugs Sales Diarrhea Suppresion , by Region K Units (2021-2026)
  • Table 307. Opioids Agonist Drugs Sales: by Receptor Binding(K Units)
  • Table 308. Opioids Agonist Drugs Sales Strong Agonist , by Region K Units (2021-2026)
  • Table 309. Opioids Agonist Drugs Sales Mild to Moderate Agonist , by Region K Units (2021-2026)
  • Table 310. South America Opioids Agonist Drugs Sales, by Country K Units (2021-2026)
  • Table 311. South America Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 312. South America Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 313. South America Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 314. Brazil Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 315. Brazil Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 316. Brazil Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 317. Argentina Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 318. Argentina Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 319. Argentina Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 320. Rest of South America Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 321. Rest of South America Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 322. Rest of South America Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 323. Asia Pacific Opioids Agonist Drugs Sales, by Country K Units (2021-2026)
  • Table 324. Asia Pacific Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 325. Asia Pacific Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 326. Asia Pacific Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 327. China Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 328. China Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 329. China Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 330. Japan Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 331. Japan Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 332. Japan Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 333. India Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 334. India Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 335. India Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 336. South Korea Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 337. South Korea Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 338. South Korea Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 339. Taiwan Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 340. Taiwan Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 341. Taiwan Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 342. Australia Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 343. Australia Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 344. Australia Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 345. Rest of Asia-Pacific Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 346. Rest of Asia-Pacific Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 347. Rest of Asia-Pacific Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 348. Europe Opioids Agonist Drugs Sales, by Country K Units (2021-2026)
  • Table 349. Europe Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 350. Europe Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 351. Europe Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 352. Germany Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 353. Germany Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 354. Germany Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 355. France Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 356. France Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 357. France Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 358. Italy Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 359. Italy Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 360. Italy Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 361. United Kingdom Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 362. United Kingdom Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 363. United Kingdom Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 364. Netherlands Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 365. Netherlands Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 366. Netherlands Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 367. Rest of Europe Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 368. Rest of Europe Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 369. Rest of Europe Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 370. MEA Opioids Agonist Drugs Sales, by Country K Units (2021-2026)
  • Table 371. MEA Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 372. MEA Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 373. MEA Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 374. Middle East Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 375. Middle East Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 376. Middle East Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 377. Africa Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 378. Africa Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 379. Africa Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 380. North America Opioids Agonist Drugs Sales, by Country K Units (2021-2026)
  • Table 381. North America Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 382. North America Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 383. North America Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 384. United States Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 385. United States Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 386. United States Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 387. Canada Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 388. Canada Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 389. Canada Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 390. Mexico Opioids Agonist Drugs Sales, by Type K Units (2021-2026)
  • Table 391. Mexico Opioids Agonist Drugs Sales, by Application K Units (2021-2026)
  • Table 392. Mexico Opioids Agonist Drugs Sales, by Receptor Binding K Units (2021-2026)
  • Table 393. Opioids Agonist Drugs: by Type(USD/Units)
  • Table 394. Research Programs/Design for This Report
  • Table 395. Key Data Information from Secondary Sources
  • Table 396. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Opioids Agonist Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Opioids Agonist Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Opioids Agonist Drugs: by Receptor Binding USD Million (2015-2020)
  • Figure 7. South America Opioids Agonist Drugs Share (%), by Country
  • Figure 8. Asia Pacific Opioids Agonist Drugs Share (%), by Country
  • Figure 9. Europe Opioids Agonist Drugs Share (%), by Country
  • Figure 10. MEA Opioids Agonist Drugs Share (%), by Country
  • Figure 11. North America Opioids Agonist Drugs Share (%), by Country
  • Figure 12. Global Opioids Agonist Drugs: by Type K Units (2015-2020)
  • Figure 13. Global Opioids Agonist Drugs: by Application K Units (2015-2020)
  • Figure 14. Global Opioids Agonist Drugs: by Receptor Binding K Units (2015-2020)
  • Figure 15. South America Opioids Agonist Drugs Share (%), by Country
  • Figure 16. Asia Pacific Opioids Agonist Drugs Share (%), by Country
  • Figure 17. Europe Opioids Agonist Drugs Share (%), by Country
  • Figure 18. MEA Opioids Agonist Drugs Share (%), by Country
  • Figure 19. North America Opioids Agonist Drugs Share (%), by Country
  • Figure 20. Global Opioids Agonist Drugs: by Type USD/Units (2015-2020)
  • Figure 21. Global Opioids Agonist Drugs share by Players 2020 (%)
  • Figure 22. Global Opioids Agonist Drugs share by Players (Top 3) 2020(%)
  • Figure 23. Global Opioids Agonist Drugs share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Purdue Pharma L.P (United States) Revenue, Net Income and Gross profit
  • Figure 26. Purdue Pharma L.P (United States) Revenue: by Geography 2020
  • Figure 27. Allergan PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 28. Allergan PLC (Ireland) Revenue: by Geography 2020
  • Figure 29. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi S.A (France) Revenue: by Geography 2020
  • Figure 31. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Janssen Pharmaceuticals, Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 34. Janssen Pharmaceuticals, Inc. (Belgium) Revenue: by Geography 2020
  • Figure 35. Endo Pharmaceuticals, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. Endo Pharmaceuticals, Inc (United States) Revenue: by Geography 2020
  • Figure 37. Actavis Plc (United States) Revenue, Net Income and Gross profit
  • Figure 38. Actavis Plc (United States) Revenue: by Geography 2020
  • Figure 39. Egalet Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 40. Egalet Corporation (United States) Revenue: by Geography 2020
  • Figure 41. Sun Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 42. Sun Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 43. Boehringer Ingelheim GmbH (Germany). Revenue, Net Income and Gross profit
  • Figure 44. Boehringer Ingelheim GmbH (Germany). Revenue: by Geography 2020
  • Figure 45. Titan Pharmaceuticals, Inc. (TTNP) (United States) Revenue, Net Income and Gross profit
  • Figure 46. Titan Pharmaceuticals, Inc. (TTNP) (United States) Revenue: by Geography 2020
  • Figure 47. Global Opioids Agonist Drugs: by Type USD Million (2021-2026)
  • Figure 48. Global Opioids Agonist Drugs: by Application USD Million (2021-2026)
  • Figure 49. Global Opioids Agonist Drugs: by Receptor Binding USD Million (2021-2026)
  • Figure 50. South America Opioids Agonist Drugs Share (%), by Country
  • Figure 51. Asia Pacific Opioids Agonist Drugs Share (%), by Country
  • Figure 52. Europe Opioids Agonist Drugs Share (%), by Country
  • Figure 53. MEA Opioids Agonist Drugs Share (%), by Country
  • Figure 54. North America Opioids Agonist Drugs Share (%), by Country
  • Figure 55. Global Opioids Agonist Drugs: by Type K Units (2021-2026)
  • Figure 56. Global Opioids Agonist Drugs: by Application K Units (2021-2026)
  • Figure 57. Global Opioids Agonist Drugs: by Receptor Binding K Units (2021-2026)
  • Figure 58. South America Opioids Agonist Drugs Share (%), by Country
  • Figure 59. Asia Pacific Opioids Agonist Drugs Share (%), by Country
  • Figure 60. Europe Opioids Agonist Drugs Share (%), by Country
  • Figure 61. MEA Opioids Agonist Drugs Share (%), by Country
  • Figure 62. North America Opioids Agonist Drugs Share (%), by Country
  • Figure 63. Global Opioids Agonist Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Purdue Pharma L.P (United States)
  • Allergan PLC (Ireland)
  • Sanofi S.A (France)
  • Pfizer, Inc. (United States)
  • Janssen Pharmaceuticals, Inc. (Belgium)
  • Endo Pharmaceuticals, Inc (United States)
  • Actavis Plc (United States)
  • Egalet Corporation (United States)
  • Sun Pharmaceuticals (India)
  • Boehringer Ingelheim GmbH (Germany).
  • Titan Pharmaceuticals, Inc. (TTNP) (United States)
Additional players considered in the study are as follows:
Mallinckrodt Pharmaceuticals (United Kingdom) , Allergan, Plc (Ireland)
Select User Access Type

Key Highlights of Report


Jul 2021 217 Pages 82 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Opioids Agonist Drugs Market Quantitative research analysis
Global Opioids Agonist Drugs Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Opioids Agonist Drugs study can be customized to meet your requirements. The market size breakdown by type [Morphine, Codeine, Fentanyl and Meperidine], by end use application [Pain Management, Cough Supression and Diarrhea Suppresion].
The Opioids Agonist Drugs Market is gaining popularity and expected to see strong valuation by 2026.
According to AMA, the Global Opioids Agonist Drugs market is expected to see growth rate of %.

Know More About Global Opioids Agonist Drugs Market Report?

Have a Query? Click Here

Other Related Reports

Citicoline Comprehensive Study by Form (Tablet, Capsule, Powder), Indication (Alzheimer’s Disease, Dementia, Head Trauma, Cerebral Ischemic Stroke, Cognitive Impairment, Others), Distribution (Hospit...
$ 3650
Recombinant Vaccines Comprehensive Study by Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines), Application (Recombinant Human Vaccines, Animal Recombin...
$ 3650
Serotonin Suppliment Comprehensive Study by Type (Tablets, Capsules, Liquid and Sprays, Others), Application (Depression Treatment, Anxiety Treatment, Others), Sales Channel (Over the Counter (OTC), ...
$ 3450
Revlimid Drug Comprehensive Study by Application (Hospital, Drugs Store, Other), Dosage (10mg, 25mg, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Prescription Drugs Comprehensive Study by Type (Opinoids, Stimulants, Depressants), Application (Hospital, Clinic, Other), End users (Adults, Children), Drug type (Brand Drugs, Generic Drug), Distrib...
$ 3350
Rheumatoid Arthritis Drug Comprehensive Study by Route of Administration (Oral, Parenteral), End-users (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharma...
$ 3750